GlassScriptPhysician profile
Kathleen A Malcolm
NPI 1548273238
$5,244.16
in general payments reported to CMS, 2019-2025
25 companies · $2,122 in 2025
The $2,122 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $1,182 · 2023: $373 · 2024: $1,086 · 2025: $2,122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,859 · Travel and Lodging: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.21 |
| Travel and Lodging | $721.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,751.02 | 2021-2025 | Evoque, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Atricure, INC. | $659.39 | 2022 | |
| Boston Scientific Corporation | $600.13 | 2021-2025 | Rhythmia Mapping System |
| Lilly USA, LLC | $271.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Corcept Therapeutics | $212.22 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $197.85 | 2023-2024 | |
| Medtronic, INC. | $187.25 | 2023-2025 | Corevalve Evolut R |
| Abbvie INC. | $175.69 | 2023-2025 | |
| Cardiac Dimensions, INC. | $159.44 | 2025 | |
| Janssen Pharmaceuticals, INC | $151.17 | 2021-2022 | |
| Abiomed | $144.47 | 2023 | Impella |
| Novo Nordisk INC | $135.63 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $129.39 | 2022-2023 | Farxiga |
| Abbott Laboratories | $123.64 | 2021-2025 | Amplatzer Amulet |
| Recordati_rare_diseases_inc. | $61.61 | 2023-2025 | Isturisa, Signifor Lar |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $48.09 | 2023-2024 | Dexcom G6 Transmitter |
| Mannkind Corporation | $37.98 | 2024 | |
| Amgen INC. | $37.50 | 2024-2025 | Evenity, Prolia, Prolia |
| Astellas Pharma US INC | $37.19 | 2021 | |
| Amneal Pharmaceuticals LLC | $29.12 | 2023-2024 | Unithroid |
| Bayer Healthcare Pharmaceuticals INC. | $26.62 | 2025 | |
| Esperion Therapeutics, INC. | $18.75 | 2024 | Nexletol |
| Avvisto Therapeutics, LLC | $17.96 | 2024 | Cycloset |
| Novartis Pharmaceuticals Corporation | $16.48 | 2025 | |
| Beta Bionics, INC. | $14.49 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Malcolm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.